| Motif ID |
Motif Logo |
Scanned Score Distribution |
Frequency of Motif |
Replicability Score |
Evolutionary Conservation Score |
Gene Targets |
Gene Ontology of CpGMM targets |
| CG_ffipsc1911_promoter_p_PM_18_32_8 |
 |
 |
2 |
0.4 |
8.71E-05 |
DAK |
FAD-AMP lyase (cyclizing) activity [MF],
glycerone kinase activity [MF],
triokinase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_14_24_10 |
 |
 |
1 |
0.2 |
1.57E-05 |
ZRANB1,
DERA,
PTK7,
HSPB1,
PRKCZ |
protein deubiquitination involved in ubiquitin-dependent protein catabolic process [BP],
deoxyribose-phosphate aldolase activity [MF],
ubiquitin binding [MF],
actin cytoskeleton reorganization [BP] |
| CG_ffipsc1911_promoter_p_PM_12_118_12 |
 |
 |
2 |
0.4 |
1.43E-04 |
FAM20C |
odontoblast differentiation [BP],
dentinogenesis [BP],
osteoclast maturation [BP] |
| CG_ffipsc1911_promoter_p_PM_12_205_15 |
 |
 |
2 |
0.4 |
1.21E-04 |
SLC25A37,
APPL1 |
regulation of establishment of protein localization to plasma membrane [BP],
mitochondrial iron ion transport [BP] |
| CG_ffipsc1911_promoter_p_PM_12_116_7 |
 |
 |
2 |
0.4 |
1.25E-04 |
ENTPD6,
WNT8A |
polarity specification of anterior/posterior axis [BP],
guanosine-5'-triphosphate,3'-diphosphate diphosphatase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_157_9 |
 |
 |
2 |
0.4 |
2.28E-04 |
AK7 |
cytidylate kinase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_114_6 |
 |
 |
2 |
0.4 |
1.03E-04 |
ADRA2C,
APOA1BP |
negative regulation of uterine smooth muscle contraction [BP],
NADHX epimerase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_16_31_18 |
 |
 |
4 |
0.8 |
4.68E-05 |
AZU1,
WNT9B |
positive regulation of fractalkine biosynthetic process [BP],
establishment of planar polarity involved in nephron morphogenesis [BP],
positive regulation of interleukin-1 beta biosynthetic process [BP] |
| CG_ffipsc1911_promoter_p_PM_12_297_4 |
 |
 |
1 |
0.2 |
2.39E-04 |
GDA |
guanine catabolic process [BP],
guanine deaminase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_119_6 |
 |
 |
2 |
0.4 |
1.23E-04 |
PCCB,
PML |
negative regulation of translation in response to oxidative stress [BP],
extrinsic to endoplasmic reticulum membrane [CC],
propionyl-CoA carboxylase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_197_7 |
 |
 |
2 |
0.4 |
1.06E-04 |
COL14A1 |
collagen type XIV [CC] |
| CG_ffipsc1911_promoter_p_PM_16_42_22 |
 |
 |
5 |
1.0 |
7.45E-05 |
PEX14,
TPGS1 |
adult behavior [BP],
protein import into peroxisome matrix [BP] |
| CG_ffipsc1911_promoter_p_PM_12_250_5 |
 |
 |
1 |
0.2 |
9.35E-05 |
IFNL1 |
negative regulation of memory T cell differentiation [BP],
interleukin-28 receptor binding [MF] |
| CG_ffipsc1911_promoter_p_PM_14_75_10 |
 |
 |
2 |
0.4 |
3.30E-05 |
BDKRB2 |
regulation of vascular permeability [BP] |
| CG_ffipsc1911_promoter_p_PM_12_51_7 |
 |
 |
2 |
0.4 |
6.20E-05 |
ADK,
F11 |
serine-type aminopeptidase activity [MF],
AMP salvage [BP],
dATP biosynthetic process [BP],
adenosine kinase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_184_5 |
 |
 |
2 |
0.4 |
7.67E-05 |
UBC,
PMAIP1 |
hypothalamus gonadotrophin-releasing hormone neuron development [BP],
negative regulation of mitochondrial membrane potential [BP] |
| CG_ffipsc1911_promoter_p_PM_14_45_18 |
 |
 |
5 |
1.0 |
3.38E-05 |
DRAXIN,
RAMP2,
MAPKAPK2 |
cellular response to vascular endothelial growth factor stimulus [BP],
commissural neuron differentiation in spinal cord [BP] |
| CG_ffipsc1911_promoter_p_PM_12_182_10 |
 |
 |
1 |
0.2 |
2.57E-05 |
VEGFB,
SERPINF2,
UGCG |
platelet alpha granule lumen [CC],
ceramide glucosyltransferase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_204_8 |
 |
 |
1 |
0.2 |
1.47E-04 |
MYO7A,
GRK4 |
cell cortex [CC] |
| CG_ffipsc1911_promoter_p_PM_14_16_5 |
 |
 |
2 |
0.4 |
8.83E-05 |
FAHD1 |
acylpyruvate hydrolase activity [MF],
fumarylpyruvate hydrolase activity [MF],
acetylpyruvate hydrolase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_14_43_10 |
 |
 |
2 |
0.4 |
4.56E-05 |
KDM4C,
BIRC5,
GABARAPL2,
KAT8 |
enzyme binding [MF],
kinetochore [CC],
interphase microtubule organizing center [CC],
microtubule binding [MF] |
| CG_ffipsc1911_promoter_p_PM_12_53_8 |
 |
 |
3 |
0.6 |
8.98E-05 |
RBM4,
AIP,
SIRT5,
CDK1 |
GAF domain binding [MF],
pronuclear fusion [BP],
circadian regulation of translation [BP],
IRES-dependent translational initiation [BP],
cap-independent translational initiation [BP],
peptidyl-lysine desuccinylation [BP],
peptidyl-lysine demalonylation [BP],
protein-succinyllysine desuccinylase activity [MF],
protein-malonyllysine demalonylase activity [MF],
pre-mRNA intronic pyrimidine-rich binding [MF] |
| CG_ffipsc1911_promoter_p_PM_12_72_7 |
 |
 |
2 |
0.4 |
7.67E-05 |
TRMT44 |
methyltransferase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_202_3 |
 |
 |
2 |
0.4 |
4.71E-05 |
OPRL1 |
nociceptin receptor activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_139_11 |
 |
 |
2 |
0.4 |
4.97E-05 |
MYH7B,
JAM3,
MYOM2 |
myosin filament [CC],
regulation of actin cytoskeleton organization by cell-cell adhesion [BP] |
| CG_ffipsc1911_promoter_p_PM_16_16_6 |
 |
 |
4 |
0.8 |
2.75E-05 |
FXN,
QPRT |
regulation of ferrochelatase activity [BP],
iron chaperone activity [MF],
quinolinate catabolic process [BP] |
| CG_ffipsc1911_promoter_p_PM_12_281_7 |
 |
 |
2 |
0.4 |
1.01E-04 |
KATNB1,
MUC2,
SLC22A5 |
sodium-dependent organic cation transport [BP],
katanin complex [CC],
positive regulation of intestinal epithelial structure maintenance [BP],
quorum sensing involved in interaction with host [BP],
inner mucus layer [CC],
outer mucus layer [CC] |
| CG_ffipsc1911_promoter_p_PM_14_68_4 |
 |
 |
1 |
0.2 |
2.58E-05 |
DDX1,
DMAP1,
PRKAA2,
IFNAR2 |
[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity [MF],
[acetyl-CoA carboxylase] kinase activity [MF],
DNA/RNA helicase activity [MF],
type I interferon receptor activity [MF],
cleavage body [CC],
type I interferon binding [MF],
chromatin binding [MF] |
| CG_ffipsc1911_promoter_p_PM_12_277_6 |
 |
 |
2 |
0.4 |
2.16E-04 |
HCRTR2 |
orexin receptor activity [MF] |
| CG_ffipsc1911_promoter_p_PM_18_25_16 |
 |
 |
4 |
0.8 |
3.77E-05 |
LAX1 |
immunoglobulin secretion [BP] |
| CG_ffipsc1911_promoter_p_PM_12_78_5 |
 |
 |
2 |
0.4 |
1.58E-04 |
TOP1,
GRIN1 |
replication fork protection complex [CC],
synaptic cleft [CC],
propylene metabolic process [BP] |
| CG_ffipsc1911_promoter_p_PM_12_165_5 |
 |
 |
1 |
0.2 |
1.92E-04 |
VLDLR,
OXA1L |
reelin receptor activity [MF],
mitochondrial proton-transporting ATP synthase complex assembly [BP],
mitochondrial ribosome binding [MF],
glycoprotein transport [BP],
very-low-density lipoprotein particle binding [MF],
glycoprotein transporter activity [MF] |
| CG_ffipsc1911_promoter_p_PM_14_12_8 |
 |
 |
3 |
0.6 |
3.80E-05 |
PSMC5,
EP300 |
nuclear proteasome complex [CC],
thyrotropin-releasing hormone receptor binding [MF],
lysine N-acetyltransferase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_14_8_5 |
 |
 |
2 |
0.4 |
5.79E-05 |
GAA,
GSTO1 |
maltose metabolic process [BP],
sucrose metabolic process [BP],
diaphragm contraction [BP],
vacuolar sequestering [BP],
positive regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion [BP] |
| CG_ffipsc1911_promoter_p_PM_12_269_11 |
 |
 |
2 |
0.4 |
1.82E-04 |
HMG20B,
GAA,
DERA |
diaphragm contraction [BP],
sucrose metabolic process [BP],
maltose metabolic process [BP],
deoxyribose-phosphate aldolase activity [MF],
negative regulation of protein sumoylation [BP],
vacuolar sequestering [BP] |
| CG_ffipsc1911_promoter_p_PM_16_6_26 |
 |
 |
2 |
0.4 |
1.09E-04 |
POLR1E |
rRNA transcription [BP] |
| CG_ffipsc1911_promoter_p_PM_12_142_4 |
 |
 |
1 |
0.2 |
2.34E-04 |
RHO |
photoreceptor inner segment membrane [CC],
red, far-red light phototransduction [BP] |
| CG_ffipsc1911_promoter_p_PM_12_60_8 |
 |
 |
3 |
0.6 |
2.80E-05 |
CAD |
response to cortisol stimulus [BP],
aspartate binding [MF],
aspartate carbamoyltransferase activity [MF],
'de novo' pyrimidine nucleobase biosynthetic process [BP],
glutamine catabolic process [BP],
'de novo' UMP biosynthetic process [BP],
carbamoyl-phosphate synthase (glutamine-hydrolyzing) activity [MF],
carbamoyl phosphate biosynthetic process [BP],
dihydroorotase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_283_5 |
 |
 |
1 |
0.2 |
3.19E-05 |
IL4,
PNMT,
ATP6V0C |
negative regulation of T-helper 17 cell differentiation [BP],
T-helper 1 cell lineage commitment [BP],
epinephrine biosynthetic process [BP],
interleukin-4 receptor binding [MF],
B cell costimulation [BP],
phenylethanolamine N-methyltransferase activity [MF],
proton transport [BP],
positive regulation of isotype switching to IgE isotypes [BP],
connective tissue growth factor biosynthetic process [BP],
cellular response to mercury ion [BP] |
| CG_ffipsc1911_promoter_p_PM_12_76_7 |
 |
 |
3 |
0.6 |
1.51E-04 |
NADSYN1,
TPCN2,
CACNG7,
CR1 |
voltage-gated calcium channel activity [MF],
complement component C3b receptor activity [MF],
positive regulation of serine-type endopeptidase activity [BP],
NAD+ synthase (glutamine-hydrolyzing) activity [MF],
negative regulation of complement activation, alternative pathway [BP],
NAADP-sensitive calcium-release channel activity [MF],
complement component C4b receptor activity [MF],
complement component C3b binding [MF],
negative regulation of serine-type endopeptidase activity [BP],
complement component C4b binding [MF],
negative regulation of complement activation, classical pathway [BP] |
| CG_ffipsc1911_promoter_p_PM_12_254_10 |
 |
 |
5 |
0.8 |
6.48E-05 |
ACOT4 |
dicarboxylic acid catabolic process [BP] |
| CG_ffipsc1911_promoter_p_PM_14_64_9 |
 |
 |
3 |
0.6 |
2.97E-05 |
RPP30,
EIF2A,
DENR,
SARS |
tRNA processing [BP],
translation initiation factor activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_198_4 |
 |
 |
2 |
0.4 |
1.14E-04 |
BIRC3,
FOXL1,
AFMID |
negative regulation of necroptosis [BP],
visceral mesoderm-endoderm interaction involved in midgut development [BP],
arylformamidase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_62_6 |
 |
 |
2 |
0.4 |
1.85E-04 |
PDIA2,
PPARA,
SART1,
P2RX2,
CARKD,
SOAT2 |
macrophage derived foam cell differentiation [BP],
regulation of glycolysis by positive regulation of transcription from RNA polymerase II promoter [BP],
regulation of cellular ketone metabolic process by positive regulation of transcription from RNA polymerase II promoter [BP],
ATP-dependent NAD(P)H-hydrate dehydratase activity [MF],
response to hypoxia [BP],
detection of hypoxic conditions in blood by carotid body chemoreceptor signaling [BP],
positive regulation of cytotoxic T cell differentiation [BP] |
| CG_ffipsc1911_promoter_p_PM_12_33_5 |
 |
 |
2 |
0.4 |
7.96E-05 |
GPD2,
ISG20 |
exoribonuclease II activity [MF],
sn-glycerol-3-phosphate:ubiquinone-8 oxidoreductase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_82_7 |
 |
 |
2 |
0.4 |
1.41E-04 |
RBPJ,
COL13A1,
KIF19,
HSPA2 |
blood vessel endothelial cell fate specification [BP],
synaptonemal complex disassembly [BP],
collagen type XIII [CC],
axonemal microtubule depolymerization [BP],
plus-end specific microtubule depolymerization [BP],
recombinase activity [MF],
positive regulation of cyclin-dependent protein kinase activity involved in G2/M [BP],
positive regulation of ephrin receptor signaling pathway [BP] |
| CG_ffipsc1911_promoter_p_PM_14_38_9 |
 |
 |
1 |
0.2 |
7.41E-05 |
TGS1,
CMPK1 |
dCDP biosynthetic process [BP],
CDP biosynthetic process [BP],
RNA trimethylguanosine synthase activity [MF],
UDP biosynthetic process [BP],
7-methylguanosine cap hypermethylation [BP] |
| CG_ffipsc1911_promoter_p_PM_18_4_10 |
 |
 |
2 |
0.4 |
4.68E-05 |
ST3GAL4,
ACO2 |
citrate hydro-lyase (cis-aconitate-forming) activity [MF],
3 iron, 4 sulfur cluster binding [MF],
isocitrate hydro-lyase (cis-aconitate-forming) activity [MF],
monosialoganglioside sialyltransferase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_261_11 |
 |
 |
2 |
0.4 |
1.93E-04 |
MERTK,
KCNAB2,
KCNMB2 |
potassium channel regulator activity [MF],
rhabdomere [CC] |
| CG_ffipsc1911_promoter_p_PM_14_49_11 |
 |
 |
2 |
0.4 |
4.47E-05 |
AP2B1,
UBC,
RAB7A |
endosomal transport [BP],
cellular membrane organization [BP],
endocytic vesicle membrane [CC],
epidermal growth factor receptor signaling pathway [BP],
negative regulation of epidermal growth factor receptor signaling pathway [BP],
hypothalamus gonadotrophin-releasing hormone neuron development [BP],
ubiquitin homeostasis [BP],
antigen processing and presentation of exogenous peptide antigen via MHC class II [BP],
epidermal growth factor catabolic process [BP] |
| CG_ffipsc1911_promoter_p_PM_12_289_7 |
 |
 |
2 |
0.4 |
7.75E-05 |
SDSL |
L-serine ammonia-lyase activity [MF],
L-threonine ammonia-lyase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_134_6 |
 |
 |
2 |
0.4 |
5.56E-05 |
TBK1,
CHRM3,
GGA1,
IFNAR1,
KDELR3,
MAVS,
PACSIN1,
PPIA,
DBNL |
type I interferon production [BP],
type I interferon biosynthetic process [BP],
endocytosis [BP],
cellular protein modification process [BP],
positive regulation of interferon-alpha production [BP],
vesicle-mediated transport [BP],
viral release from host cell [BP] |
| CG_ffipsc1911_promoter_p_PM_12_286_13 |
 |
 |
1 |
0.2 |
9.93E-05 |
INPP5F,
SLC38A3,
TLR3 |
asparagine transport [BP],
histidine transport [BP],
phosphatidylinositol catabolic process [BP],
positive regulation of type III interferon production [BP] |
| CG_ffipsc1911_promoter_p_PM_14_32_16 |
 |
 |
3 |
0.6 |
5.57E-05 |
TRIM28,
PIM1,
CREB1,
NUP188,
NUDT16,
NUPL1,
EIF5A,
DCP2 |
m7G(5')pppN diphosphatase activity [MF],
manganese ion binding [MF],
nuclear pore [CC],
nuclear euchromatin [CC] |
| CG_ffipsc1911_promoter_p_PM_12_23_6 |
 |
 |
2 |
0.4 |
2.68E-05 |
ASXL1 |
PR-DUB complex [CC],
monoubiquitinated histone H2A deubiquitination [BP],
negative regulation of peroxisome proliferator activated receptor signaling pathway [BP] |
| CG_ffipsc1911_promoter_p_PM_16_7_14 |
 |
 |
4 |
0.8 |
5.22E-05 |
PTPN13,
SLC9A8,
CHP1,
SPIRE2,
MAST1,
FRMPD1,
LLGL1 |
cytoskeleton [CC],
regulation of intracellular pH [BP] |
| CG_ffipsc1911_promoter_p_PM_12_242_9 |
 |
 |
2 |
0.4 |
1.73E-04 |
POLA1 |
leading strand elongation [BP] |
| CG_ffipsc1911_promoter_p_PM_12_211_6 |
 |
 |
1 |
0.2 |
1.06E-04 |
NGFR,
TMEM126A |
optic nerve development [BP],
nerve development [BP] |
| CG_ffipsc1911_promoter_p_PM_16_41_15 |
 |
 |
2 |
0.4 |
4.26E-05 |
MAP3K1,
WNT8B,
ST3GAL6,
MAP2K1 |
activation of MAPKK activity [BP],
negative regulation of anterior neural cell fate commitment of the neural plate by Wnt receptor signaling pathway [BP],
protein serine/threonine/tyrosine kinase activity [MF],
receptor signaling protein tyrosine phosphatase activity [MF],
beta-galactoside alpha-2,3-sialyltransferase activity [MF],
MAP kinase kinase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_167_4 |
 |
 |
2 |
0.4 |
2.08E-04 |
PAPD7 |
SMC family protein binding [MF] |
| CG_ffipsc1911_promoter_p_PM_12_251_6 |
 |
 |
1 |
0.2 |
2.26E-05 |
TPI1,
TAS1R3 |
sweet taste receptor activity [MF],
detection of chemical stimulus involved in sensory perception of sweet taste [BP],
glyceraldehyde-3-phosphate metabolic process [BP],
triose-phosphate isomerase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_90_12 |
 |
 |
2 |
0.4 |
4.49E-05 |
VIL1 |
cytoplasmic actin-based contraction involved in cell motility [BP],
positive regulation of actin filament bundle assembly [BP],
lysophosphatidic acid binding [MF] |
| CG_ffipsc1911_promoter_p_PM_16_26_11 |
 |
 |
3 |
0.6 |
7.83E-05 |
GHR,
CFLAR,
AHSA1,
APOC1,
UTS2R,
BAG2 |
negative regulation of phosphatidylcholine catabolic process [BP],
growth hormone receptor activity [MF],
chaperone binding [MF],
negative regulation of myoblast fusion [BP],
enzyme activator activity [MF],
urotensin II receptor activity [MF],
growth hormone receptor complex [CC] |
| CG_ffipsc1911_promoter_p_PM_14_39_8 |
 |
 |
2 |
0.4 |
4.10E-05 |
MET,
MPP5,
ARHGEF18 |
protein localization to myelin sheath abaxonal region [BP],
hepatocyte growth factor-activated receptor activity [MF],
Rho guanyl-nucleotide exchange factor activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_19_7 |
 |
 |
2 |
0.4 |
1.24E-04 |
ASL |
arginine biosynthetic process via ornithine [BP],
argininosuccinate lyase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_147_4 |
 |
 |
4 |
0.8 |
3.35E-05 |
CHD1L,
HMGA1,
HTR3A |
oncogene-induced senescence [BP],
chromatin remodeling [BP],
serotonin-activated cation-selective channel activity [MF] |
| CG_ffipsc1911_promoter_p_PM_14_50_7 |
 |
 |
4 |
0.8 |
3.55E-05 |
GALM |
aldose 1-epimerase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_189_8 |
 |
 |
2 |
0.4 |
4.61E-05 |
MRAP,
SUFU,
FZD3 |
cell proliferation in midbrain [BP],
type 5 melanocortin receptor binding [MF],
neural tube closure [BP],
corticotropin hormone receptor binding [MF] |
| CG_ffipsc1911_promoter_p_PM_12_14_6 |
 |
 |
2 |
0.4 |
3.16E-05 |
GAA |
maltose metabolic process [BP],
sucrose metabolic process [BP],
diaphragm contraction [BP],
vacuolar sequestering [BP] |
| CG_ffipsc1911_promoter_p_PM_12_206_13 |
 |
 |
2 |
0.4 |
1.53E-04 |
NUS1,
COX10 |
heme a biosynthetic process [BP],
farnesyltranstransferase activity [MF],
cytochrome complex assembly [BP],
transferase activity, transferring alkyl or aryl (other than methyl) groups [MF],
heme O biosynthetic process [BP],
mitochondrial electron transport, cytochrome c to oxygen [BP],
protoheme IX farnesyltransferase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_18_11_59 |
 |
 |
5 |
0.8 |
4.90E-05 |
RPF1,
WNT6,
BAMBI,
RPL11,
CREBL2,
CDH1,
PPP1R16B,
ZSCAN21,
BRCA2 |
rRNA binding [MF],
protein phosphatase binding [MF],
positive regulation of transcription, DNA-dependent [BP] |
| CG_ffipsc1911_promoter_p_PM_16_33_24 |
 |
 |
2 |
0.4 |
3.41E-05 |
PRUNE,
PIM1,
CPA2,
NPEPL1,
CREB1,
CPA5,
CNDP2,
HHEX |
negative regulation of transcription by competitive promoter binding [BP],
manganese ion binding [MF],
metallocarboxypeptidase activity [MF],
metalloexopeptidase activity [MF],
metallopeptidase activity [MF],
carboxypeptidase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_280_10 |
 |
 |
4 |
0.8 |
9.92E-05 |
IDNK |
D-gluconate catabolic process [BP],
gluconokinase activity [MF],
shikimate kinase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_259_18 |
 |
 |
2 |
0.4 |
1.15E-04 |
IKZF1,
HPN,
AXL,
NUDT1,
ASS1 |
positive regulation of neutrophil differentiation [BP],
ATP diphosphatase activity [MF],
argininosuccinate synthase activity [MF],
basement membrane disassembly [BP],
natural killer cell differentiation [BP] |
| CG_ffipsc1911_promoter_p_PM_12_156_7 |
 |
 |
3 |
0.6 |
3.32E-05 |
PNPLA3 |
mono-olein transacylation activity [MF],
diolein transacylation activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_246_9 |
 |
 |
3 |
0.6 |
2.63E-05 |
MSH3 |
loop DNA binding [MF],
dinucleotide insertion or deletion binding [MF],
dinucleotide repeat insertion binding [MF],
maintenance of DNA repeat elements [BP],
MutSbeta complex [CC],
double-strand/single-strand DNA junction binding [MF],
single guanine insertion binding [MF],
meiotic mismatch repair [BP] |
| CG_ffipsc1911_promoter_p_PM_12_196_6 |
 |
 |
2 |
0.4 |
3.65E-05 |
RNF2 |
RING-like zinc finger domain binding [MF] |
| CG_ffipsc1911_promoter_p_PM_12_12_11 |
 |
 |
2 |
0.4 |
6.03E-05 |
CACNG6,
GRM7 |
voltage-gated calcium channel activity [MF],
adenylate cyclase inhibitor activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_39_8 |
 |
 |
2 |
0.4 |
5.86E-05 |
PAFAH1B1,
KLC3 |
astral microtubule [CC],
cardiolipin synthase activity [MF],
establishment of centrosome localization [BP],
kinesin complex [CC] |
| CG_ffipsc1911_promoter_p_PM_12_209_7 |
 |
 |
2 |
0.4 |
4.33E-05 |
AQP8,
RALA |
intracellular canaliculus [CC],
Edg-2 lysophosphatidic acid receptor binding [MF] |
| CG_ffipsc1911_promoter_p_PM_14_70_13 |
 |
 |
3 |
0.6 |
5.49E-05 |
CTNS |
compound eye corneal lens development [BP] |
| CG_ffipsc1911_promoter_p_PM_12_276_4 |
 |
 |
1 |
0.2 |
1.43E-04 |
PDX1,
L3MBTL1 |
core promoter sequence-specific DNA binding [MF],
SAM domain binding [MF] |
| CG_ffipsc1911_promoter_p_PM_12_267_11 |
 |
 |
3 |
0.6 |
3.64E-05 |
PPP1R8,
ALDH5A1 |
ribonuclease E activity [MF],
succinate-semialdehyde dehydrogenase (NAD+) activity [MF],
succinate-semialdehyde dehydrogenase [NAD(P)+] activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_257_5 |
 |
 |
3 |
0.6 |
4.05E-05 |
D2HGDH |
(R)-2-hydroxyglutarate dehydrogenase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_136_14 |
 |
 |
3 |
0.6 |
1.47E-04 |
CARTPT |
positive regulation of epinephrine secretion [BP] |
| CG_ffipsc1911_promoter_p_PM_14_40_6 |
 |
 |
1 |
0.2 |
6.05E-05 |
MSH2,
TGM4,
GALM |
aldose 1-epimerase activity [MF],
negative regulation of reciprocal meiotic recombination [BP],
protein polyamination [BP] |
| CG_ffipsc1911_promoter_p_PM_12_77_5 |
 |
 |
1 |
0.2 |
1.60E-04 |
TOR1B,
TOR4A |
chaperone mediated protein folding requiring cofactor [BP] |
| CG_ffipsc1911_promoter_p_PM_16_43_10 |
 |
 |
2 |
0.4 |
2.90E-05 |
TRAPPC5,
UBE2V2 |
TRAPP complex [CC],
UBC13-MMS2 complex [CC] |
| CG_ffipsc1911_promoter_p_PM_12_293_5 |
 |
 |
1 |
0.2 |
6.69E-05 |
SLC35A3,
SH2B2 |
UDP-N-acetylglucosamine transmembrane transporter activity [MF],
JAK pathway signal transduction adaptor activity [MF],
UDP-N-acetylglucosamine transport [BP] |
| CG_ffipsc1911_promoter_p_PM_12_193_6 |
 |
 |
2 |
0.4 |
8.29E-05 |
GCDH,
ULK1 |
radial glia guided migration of cerebellar granule cell [BP],
glutaryl-CoA dehydrogenase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_75_9 |
 |
 |
4 |
0.8 |
1.25E-04 |
GSTP1,
CHRD,
AGRN |
nitric oxide storage [BP],
positive regulation of synaptic growth at neuromuscular junction [BP],
BMP signaling pathway involved in spinal cord dorsal/ventral patterning [BP] |
| CG_ffipsc1911_promoter_p_PM_12_274_6 |
 |
 |
2 |
0.4 |
1.73E-05 |
TRNT1,
RASA2,
TNK1 |
tRNA 3'-terminal CCA addition [BP],
ATP:3'-cytidine-cytidine-tRNA adenylyltransferase activity [MF],
tRNA nucleotidyltransferase activity [MF],
CTP:tRNA cytidylyltransferase activity [MF],
tRNA adenylyltransferase activity [MF],
CTP:3'-cytidine-tRNA cytidylyltransferase activity [MF],
negative regulation of Ras protein signal transduction [BP] |
| CG_ffipsc1911_promoter_p_PM_18_15_34 |
 |
 |
4 |
0.8 |
9.58E-05 |
TMED2,
IQGAP2,
COPG1,
SLC27A4 |
COPI coating of Golgi vesicle [BP],
microvillus [CC],
COPI-coated vesicle membrane [CC] |
| CG_ffipsc1911_promoter_p_PM_12_203_8 |
 |
 |
2 |
0.4 |
6.41E-05 |
KLHL17 |
POZ domain binding [MF] |
| CG_ffipsc1911_promoter_p_PM_12_161_5 |
 |
 |
1 |
0.2 |
4.21E-05 |
UPB1 |
beta-ureidopropionase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_35_5 |
 |
 |
1 |
0.2 |
1.08E-04 |
FCER1A |
positive regulation of interleukin-3 biosynthetic process [BP],
positive regulation of type I hypersensitivity [BP],
IgE receptor activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_195_10 |
 |
 |
2 |
0.4 |
1.20E-04 |
CLEC18C,
ZP3 |
positive regulation of type IV hypersensitivity [BP],
positive regulation of antral ovarian follicle growth [BP],
positive regulation of phosphatidylinositol biosynthetic process [BP],
positive regulation of acrosomal vesicle exocytosis [BP],
positive regulation of ovarian follicle development [BP],
carbohydrate binding [MF] |
| CG_ffipsc1911_promoter_p_PM_12_237_8 |
 |
 |
3 |
0.6 |
4.98E-05 |
PAN3 |
positive regulation of cytoplasmic mRNA processing body assembly [BP],
nucleic acid binding [MF] |
| CG_ffipsc1911_promoter_p_PM_12_164_9 |
 |
 |
3 |
0.6 |
1.81E-05 |
ALG1 |
chitobiosyldiphosphodolichol beta-mannosyltransferase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_253_9 |
 |
 |
5 |
0.8 |
7.16E-05 |
BAI3,
NCKAP1L,
VASH1,
ACVR1B,
TEK |
positive regulation of erythrocyte differentiation [BP],
negative regulation of angiogenesis [BP] |
| CG_ffipsc1911_promoter_p_PM_16_47_73 |
 |
 |
6 |
1.0 |
5.95E-05 |
SCGB1A1,
FGFR3,
NTRK1,
IFNL1 |
negative regulation of interleukin-13 production [BP],
negative regulation of interleukin-5 production [BP],
axonogenesis involved in innervation [BP] |
| CG_ffipsc1911_promoter_p_PM_14_61_10 |
 |
 |
5 |
0.8 |
4.10E-05 |
NR1H2 |
positive regulation of pancreatic juice secretion [BP],
negative regulation of pinocytosis [BP],
positive regulation of secretion of lysosomal enzymes [BP],
positive regulation of high-density lipoprotein particle assembly [BP],
sequence-specific transcription regulatory region DNA binding RNA polymerase II transcription factor recruiting transcription factor activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_97_11 |
 |
 |
4 |
0.8 |
7.01E-05 |
CHST2 |
N-acetylglucosamine 6-O-sulfotransferase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_14_13_8 |
 |
 |
2 |
0.4 |
8.58E-05 |
CRCP,
PTDSS2,
PARVB |
establishment or maintenance of cell polarity regulating cell shape [BP],
DNA polymerase III complex [CC],
CDP-diacylglycerol-serine O-phosphatidyltransferase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_63_12 |
 |
 |
2 |
0.4 |
3.28E-05 |
MCHR1,
FURIN,
PRMT7 |
[myelin basic protein]-arginine N-methyltransferase activity [MF],
peptidyl-arginine methylation, to symmetrical-dimethyl arginine [BP],
histone methyltransferase activity (H4-R3 specific) [MF],
histone methylation [BP],
nerve growth factor production [BP],
negative regulation of transforming growth factor beta1 production [BP],
melanin-concentrating hormone receptor activity [MF],
negative regulation of low-density lipoprotein particle receptor catabolic process [BP],
protein-arginine omega-N symmetric methyltransferase activity [MF],
S-adenosylmethionine-dependent methyltransferase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_240_16 |
 |
 |
5 |
0.8 |
6.98E-05 |
CSF1,
PPARA,
OPRL1 |
mammary gland fat development [BP],
regulation of glycolysis by positive regulation of transcription from RNA polymerase II promoter [BP],
nociceptin receptor activity [MF],
regulation of macrophage derived foam cell differentiation [BP],
regulation of cellular ketone metabolic process by positive regulation of transcription from RNA polymerase II promoter [BP] |
| CG_ffipsc1911_promoter_p_PM_16_3_11 |
 |
 |
2 |
0.4 |
7.01E-05 |
CHAT,
GRHPR |
choline O-acetyltransferase activity [MF],
glycerate dehydrogenase activity [MF],
hydroxypyruvate reductase activity [MF],
glyoxylate reductase (NADP) activity [MF] |
| CG_ffipsc1911_promoter_p_PM_18_19_14 |
 |
 |
3 |
0.6 |
3.16E-05 |
CSF2RB,
WRN |
multicellular organismal aging [BP],
granulocyte macrophage colony-stimulating factor receptor complex [CC] |
| CG_ffipsc1911_promoter_p_PM_12_30_6 |
 |
 |
5 |
0.8 |
2.62E-05 |
RPS15,
BRDT |
ribosomal small subunit export from nucleus [BP],
histone displacement [BP],
positive regulation of transcription during meiosis [BP] |
| CG_ffipsc1911_promoter_p_PM_12_79_5 |
 |
 |
3 |
0.6 |
6.03E-05 |
DDX3X |
positive regulation of chemokine (C-C motif) ligand 5 production [BP],
RNA secondary structure unwinding [BP],
RNA stem-loop binding [MF] |
| CG_ffipsc1911_promoter_p_PM_12_162_4 |
 |
 |
1 |
0.2 |
1.13E-04 |
KDM4A,
ARHGAP8,
CD40,
RBX1,
LHX1 |
positive regulation of Rho GTPase activity [BP],
uterine epithelium development [BP],
ubiquitin protein ligase binding [MF],
horizontal cell localization [BP],
regulation of gene expression [BP],
nephric duct elongation [BP],
oviduct epithelium development [BP] |
| CG_ffipsc1911_promoter_p_PM_12_249_11 |
 |
 |
3 |
0.6 |
3.52E-05 |
ACE,
ADAMTS13 |
peptide catabolic process [BP] |
| CG_ffipsc1911_promoter_p_PM_12_183_6 |
 |
 |
2 |
0.4 |
5.84E-05 |
FTO,
HTT |
neural plate formation [BP],
diazepam binding [MF],
oxidative DNA demethylase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_18_6_37 |
 |
 |
2 |
0.4 |
7.87E-05 |
GJA1 |
vascular transport [BP] |
| CG_ffipsc1911_promoter_p_PM_12_31_9 |
 |
 |
3 |
0.6 |
2.43E-04 |
CDKN1A,
ALOX12,
CCKBR |
gastrin receptor activity [MF],
hepoxilin-epoxide hydrolase activity [MF],
cyclin-dependent protein kinase activating kinase activity [MF],
type B gastrin/cholecystokinin receptor binding [MF] |
| CG_ffipsc1911_promoter_p_PM_14_72_9 |
 |
 |
2 |
0.4 |
8.99E-05 |
ITGA6,
ITGB3 |
integrin complex [CC],
negative regulation of lipid transport [BP] |
| CG_ffipsc1911_promoter_p_PM_12_24_11 |
 |
 |
3 |
0.6 |
5.98E-05 |
TCF7,
JDP2,
TEF,
TRIM22,
SRGN,
POU3F3 |
maintenance of granzyme B location in T cell secretory granule [BP],
T cell secretory granule organization [BP],
metanephric macula densa development [BP],
maintenance of protease location in mast cell secretory granule [BP],
sequence-specific DNA binding transcription factor activity [MF] |
| CG_ffipsc1911_promoter_p_PM_14_63_15 |
 |
 |
2 |
0.4 |
3.54E-05 |
MED18,
MALSU1,
THRAP3,
SHBG |
negative regulation of mitochondrial translation [BP],
mediator complex [CC],
primary spermatocyte growth [BP] |
| CG_ffipsc1911_promoter_p_PM_12_18_5 |
 |
 |
1 |
0.2 |
6.05E-05 |
IFIT2,
PARK7 |
positive regulation of oxidative phosphorylation uncoupler activity [BP],
negative regulation of protein binding [BP] |
| CG_ffipsc1911_promoter_p_PM_12_247_22 |
 |
 |
7 |
0.8 |
1.30E-05 |
AKR1C1,
PDGFRA |
platelet-derived growth factor receptor-alpha signaling pathway [BP],
platelet-derived growth factor alpha-receptor activity [MF],
17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase activity [MF],
indanol dehydrogenase activity [MF],
androsterone dehydrogenase (B-specific) activity [MF],
vascular endothelial growth factor binding [MF],
phenanthrene 9,10-monooxygenase activity [MF],
ketosteroid monooxygenase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_146_8 |
 |
 |
3 |
0.6 |
7.85E-05 |
CD52 |
respiratory burst [BP] |
| CG_ffipsc1911_promoter_p_PM_12_152_16 |
 |
 |
3 |
0.6 |
2.94E-04 |
EPX,
USPL1 |
SUMO-specific isopeptidase activity [MF],
Cajal body organization [BP],
defense response to nematode [BP] |
| CG_ffipsc1911_promoter_p_PM_12_45_11 |
 |
 |
1 |
0.2 |
3.00E-06 |
GCNT1 |
beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_16_45_8 |
 |
 |
1 |
0.2 |
1.30E-04 |
DAG1,
PTGS1 |
cyclooxygenase pathway [BP],
cell outer membrane [CC],
nerve maturation [BP],
prostaglandin-endoperoxide synthase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_263_7 |
 |
 |
3 |
0.6 |
2.60E-04 |
SLC27A3,
IDUA,
RALB |
regulation of exocyst localization [BP],
regulation of exocyst assembly [BP],
fatty-acyl-CoA synthase activity [MF],
L-iduronidase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_218_7 |
 |
 |
3 |
0.6 |
2.93E-05 |
HS3ST2 |
[heparan sulfate]-glucosamine 3-sulfotransferase 2 activity [MF] |
| CG_ffipsc1911_promoter_p_PM_16_21_30 |
 |
 |
6 |
0.8 |
5.65E-05 |
D2HGDH,
PAN3 |
response to cobalt ion [BP],
positive regulation of cytoplasmic mRNA processing body assembly [BP],
(R)-2-hydroxyglutarate dehydrogenase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_148_6 |
 |
 |
2 |
0.4 |
2.49E-05 |
GAR1 |
snRNA pseudouridine synthesis [BP],
box H/ACA snoRNP complex [CC] |
| CG_ffipsc1911_promoter_p_PM_12_96_9 |
 |
 |
2 |
0.4 |
2.92E-05 |
ELANE |
negative regulation of chemokine biosynthetic process [BP] |
| CG_ffipsc1911_promoter_p_PM_14_74_6 |
 |
 |
1 |
0.2 |
1.63E-04 |
LMTK2,
HDAC1 |
peptidyl-threonine phosphorylation [BP],
core promoter binding [MF],
myosin VI binding [MF] |
| CG_ffipsc1911_promoter_p_PM_12_37_6 |
 |
 |
2 |
0.4 |
1.46E-04 |
DAG1,
CACNA1G,
ALKBH3 |
response to nickel cation [BP],
nerve maturation [BP],
oxidative single-stranded DNA demethylation [BP] |
| CG_ffipsc1911_promoter_p_PM_12_128_8 |
 |
 |
1 |
0.2 |
1.28E-04 |
UNC45A,
UNC45B,
TSEN34 |
chaperone-mediated protein folding [BP],
Hsp90 protein binding [MF],
tRNA-type intron splice site recognition and cleavage [BP] |
| CG_ffipsc1911_promoter_p_PM_18_13_22 |
 |
 |
4 |
0.8 |
3.17E-05 |
RAB8B |
cell tip [CC] |
| CG_ffipsc1911_promoter_p_PM_14_22_9 |
 |
 |
2 |
0.4 |
4.02E-05 |
GAB1,
IL6 |
interleukin-6-mediated signaling pathway [BP] |
| CG_ffipsc1911_promoter_p_PM_12_125_10 |
 |
 |
3 |
0.6 |
7.18E-05 |
CLYBL |
citrate lyase complex [CC],
citrate (pro-3S)-lyase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_14_78_13 |
 |
 |
4 |
0.8 |
7.66E-05 |
IREB2,
MEST,
SIRT4,
ASXL1 |
response to retinoic acid [BP],
protein ADP-ribosylation [BP] |
| CG_ffipsc1911_promoter_p_PM_18_30_21 |
 |
 |
5 |
0.8 |
3.34E-05 |
HKDC1,
PFKP,
HK2 |
fructokinase activity [MF],
glucokinase activity [MF],
glucose 6-phosphate metabolic process [BP],
hexokinase activity [MF],
mannokinase activity [MF],
glycolysis [BP] |
| CG_ffipsc1911_promoter_p_PM_12_223_8 |
 |
 |
2 |
0.4 |
9.48E-05 |
IRX1,
ADORA1 |
negative regulation of circadian sleep/wake cycle, non-REM sleep [BP],
negative regulation of mucus secretion [BP],
positive regulation of nucleoside transport [BP],
proximal/distal pattern formation involved in metanephric nephron development [BP],
negative regulation of neurotrophin production [BP] |
| CG_ffipsc1911_promoter_p_PM_16_30_29 |
 |
 |
6 |
1.0 |
8.19E-06 |
BIRC3,
RARA |
negative regulation of necroptosis [BP],
Sertoli cell fate commitment [BP] |
| CG_ffipsc1911_promoter_p_PM_12_191_8 |
 |
 |
2 |
0.4 |
3.40E-05 |
TRMU,
SWSAP1,
WDYHV1 |
Shu complex [CC],
protein-N-terminal glutamine amidohydrolase activity [MF],
tRNA (5-methylaminomethyl-2-thiouridylate)-methyltransferase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_18_7_31 |
 |
 |
2 |
0.4 |
4.37E-05 |
TNF,
KIT,
ARL6IP5 |
stem cell factor receptor activity [MF],
positive regulation of translational initiation by iron [BP],
L-glutamate transport [BP],
melanocyte migration [BP],
protease binding [MF],
negative regulation of branching involved in lung morphogenesis [BP],
negative regulation of L-glutamate transport [BP],
positive regulation of mononuclear cell migration [BP],
melanocyte adhesion [BP] |
| CG_ffipsc1911_promoter_p_PM_18_18_13 |
 |
 |
4 |
0.8 |
7.74E-05 |
RPA1,
RAC1,
RAD17 |
cerebral cortex radially oriented cell migration [BP],
DNA replication [BP] |
| CG_ffipsc1911_promoter_p_PM_12_256_6 |
 |
 |
2 |
0.4 |
1.02E-04 |
HTRA1,
PPP1R15A |
negative regulation of transforming growth factor beta receptor signaling pathway [BP] |
| CG_ffipsc1911_promoter_p_PM_12_208_3 |
 |
 |
2 |
0.4 |
1.54E-04 |
PNRC2 |
deadenylation-independent decapping of nuclear-transcribed mRNA [BP] |
| CG_ffipsc1911_promoter_p_PM_12_52_11 |
 |
 |
3 |
0.6 |
2.86E-05 |
RGCC,
AR |
positive regulation of extracellular matrix constituent secretion [BP],
negative regulation of fibroblast growth factor production [BP],
lateral sprouting involved in mammary gland duct morphogenesis [BP],
negative regulation of epithelial cell proliferation [BP],
POU domain binding [MF],
negative regulation of integrin biosynthetic process [BP],
negative regulation of exit from mitosis [BP],
regulation of M/G1 transition of mitotic cell cycle [BP],
male somatic sex determination [BP],
positive regulation of gene expression involved in extracellular matrix organization [BP],
activation of prostate induction by androgen receptor signaling pathway [BP] |
| CG_ffipsc1911_promoter_p_PM_12_4_10 |
 |
 |
3 |
0.4 |
1.10E-04 |
IGF2BP1 |
dendritic spine [CC],
regulation of mRNA stability involved in response to stress [BP] |
| CG_ffipsc1911_promoter_p_PM_12_124_4 |
 |
 |
1 |
0.2 |
1.02E-04 |
SLC5A2,
POR,
GPI,
HKDC1 |
glucose 6-phosphate metabolic process [BP],
iron-cytochrome-c reductase activity [MF],
low-affinity glucose:sodium symporter activity [MF],
glucose-6-phosphate isomerase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_298_4 |
 |
 |
2 |
0.4 |
2.16E-05 |
SENP6,
IDO2,
PPP4R2,
MRI1,
HAT1 |
regulation of kinetochore assembly [BP],
S-methyl-5-thioribose-1-phosphate isomerase activity [MF],
L-methionine biosynthetic process from S-adenosylmethionine [BP],
chromatin silencing at telomere [BP],
protein phosphatase type 4 regulator activity [MF],
indoleamine 2,3-dioxygenase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_38_3 |
 |
 |
1 |
0.2 |
1.08E-04 |
FPGS,
HIF1AN |
peptidyl-histidine hydroxylation [BP],
peptidyl-asparagine 3-dioxygenase activity [MF],
tetrahydrofolylpolyglutamate synthase activity [MF],
peptidyl-asparagine hydroxylation [BP],
peptidyl-histidine dioxygenase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_16_2_22 |
 |
 |
4 |
0.8 |
4.18E-05 |
SOX17,
ENOPH1 |
inner cell mass cellular morphogenesis [BP],
acireductone synthase activity [MF],
cardiogenic plate morphogenesis [BP],
regulation of transcription from RNA polymerase II promoter involved in definitive endodermal cell fate specification [BP] |
| CG_ffipsc1911_promoter_p_PM_14_15_13 |
 |
 |
3 |
0.6 |
7.46E-05 |
RARA,
MCM10,
RBL2,
ZNF740,
MTR,
PRDX5,
MC1R,
PKNOX2,
EBF4,
GCDH,
ZNF576,
SET,
MYRF,
AXL,
CSDC2 |
apoptotic cell clearance [BP],
negative regulation of interferon-gamma production [BP],
protein kinase B signaling cascade [BP],
regulation of transcription, DNA-dependent [BP],
positive regulation of protein kinase B signaling cascade [BP],
negative regulation of tumor necrosis factor production [BP],
regulation of RNA biosynthetic process [BP],
DNA binding [MF],
cellular nitrogen compound metabolic process [BP] |
| CG_ffipsc1911_promoter_p_PM_12_190_22 |
 |
 |
3 |
0.6 |
1.74E-05 |
CCDC64 |
Golgi to secretory granule transport [BP] |
| CG_ffipsc1911_promoter_p_PM_12_101_9 |
 |
 |
2 |
0.4 |
7.20E-06 |
CNST,
TRIM32 |
positive regulation of Golgi to plasma membrane protein transport [BP],
connexin binding [MF],
striated muscle myosin thick filament [CC] |
| CG_ffipsc1911_promoter_p_PM_14_60_7 |
 |
 |
2 |
0.4 |
3.00E-05 |
UGCG |
ceramide glucosyltransferase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_14_26_8 |
 |
 |
3 |
0.6 |
1.87E-05 |
UBA52,
EIF2B5,
LCN2,
EIF4A2,
MDK |
translation initiation factor activity [MF],
regulation of translational initiation [BP],
defecation [BP],
gene expression [BP],
translational initiation [BP],
positive regulation of gene expression [BP] |
| CG_ffipsc1911_promoter_p_PM_12_28_9 |
 |
 |
4 |
0.8 |
1.17E-05 |
CEL |
protein esterification [BP],
intestinal lipid catabolic process [BP],
sterol esterase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_16_25_17 |
 |
 |
3 |
0.6 |
1.03E-04 |
MSH2,
NAGS,
GALR3 |
loop DNA binding [MF],
dinucleotide insertion or deletion binding [MF],
galanin receptor activity [MF],
meiotic gene conversion [BP],
MutSbeta complex [CC],
meiotic mismatch repair [BP],
maintenance of DNA repeat elements [BP],
negative regulation of reciprocal meiotic recombination [BP],
guanine/thymine mispair binding [MF],
arginine biosynthetic process [BP],
single thymine insertion binding [MF],
oxidized purine DNA binding [MF],
double-strand/single-strand DNA junction binding [MF],
single guanine insertion binding [MF],
dinucleotide repeat insertion binding [MF],
acetyl-CoA:L-glutamate N-acetyltransferase activity [MF],
MutSalpha complex [CC] |
| CG_ffipsc1911_promoter_p_PM_12_107_18 |
 |
 |
3 |
0.6 |
1.96E-04 |
DOPEY2,
CAV2 |
endoplasmic reticulum organization [BP] |
| CG_ffipsc1911_promoter_p_PM_18_22_16 |
 |
 |
4 |
0.8 |
2.15E-05 |
AGRN |
positive regulation of synaptic growth at neuromuscular junction [BP] |
| CG_ffipsc1911_promoter_p_PM_16_44_39 |
 |
 |
5 |
1.0 |
6.54E-05 |
DCK,
TBCE |
phosphotransferase activity, alcohol group as acceptor [MF],
muscle atrophy [BP] |
| CG_ffipsc1911_promoter_p_PM_18_14_20 |
 |
 |
4 |
0.8 |
7.17E-05 |
RGS9,
RGS20 |
termination of G-protein coupled receptor signaling pathway [BP] |
| CG_ffipsc1911_promoter_p_PM_12_221_5 |
 |
 |
3 |
0.6 |
1.88E-05 |
TCF21,
FAR2,
IL18BP |
fatty-acyl-CoA reductase (alcohol-forming) activity [MF],
interleukin-18 binding [MF],
long-chain-fatty-acyl-CoA reductase activity [MF],
bronchiole development [BP],
branchiomeric skeletal muscle development [BP],
metanephric glomerular capillary formation [BP] |
| CG_ffipsc1911_promoter_p_PM_18_16_21 |
 |
 |
4 |
0.8 |
6.21E-05 |
NCAPD2 |
condensin core heterodimer [CC] |
| CG_ffipsc1911_promoter_p_PM_18_31_16 |
 |
 |
4 |
0.8 |
5.16E-05 |
KLHL20 |
interferon-gamma binding [MF] |
| CG_ffipsc1911_promoter_p_PM_12_103_7 |
 |
 |
2 |
0.4 |
1.38E-04 |
NAA60,
KIAA1324 |
N-terminal peptidyl-methionine acetylation [BP],
positive regulation of vacuole organization [BP],
positive regulation of autophagic vacuole assembly [BP] |
| CG_ffipsc1911_promoter_p_PM_12_120_8 |
 |
 |
3 |
0.6 |
3.70E-04 |
NNMT |
nicotinamide N-methyltransferase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_86_6 |
 |
 |
2 |
0.4 |
1.58E-04 |
FASLG,
TOP1,
DBH |
replication fork protection complex [CC],
activation of necroptosis of activated-T cells [BP],
chromaffin granule lumen [CC] |
| CG_ffipsc1911_promoter_p_PM_12_229_6 |
 |
 |
3 |
0.6 |
1.27E-04 |
QPCT,
HTRA3,
PRSS21 |
serine-type endopeptidase activity [MF],
peptidyl-pyroglutamic acid biosynthetic process, using glutaminyl-peptide cyclotransferase [BP],
serine-type peptidase activity [MF],
peptidase activity [MF],
glutaminyl-peptide cyclotransferase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_17_17 |
 |
 |
4 |
0.6 |
1.23E-04 |
ELK3,
GTPBP4 |
negative regulation of collagen binding [BP],
purine-rich negative regulatory element binding [MF] |
| CG_ffipsc1911_promoter_p_PM_12_255_10 |
 |
 |
2 |
0.4 |
3.34E-05 |
CDH15,
NOS3 |
negative regulation of muscle hyperplasia [BP],
caveola [CC],
adherens junction organization [BP],
smooth muscle hyperplasia [BP] |
| CG_ffipsc1911_promoter_p_PM_14_66_6 |
 |
 |
4 |
0.6 |
1.26E-05 |
SNCG,
ISCU |
cellular response to hydrostatic pressure [BP],
nitrogen fixation [BP] |
| CG_ffipsc1911_promoter_p_PM_12_1_10 |
 |
 |
1 |
0.2 |
2.58E-04 |
TEK,
KANK1,
CLEC4M |
substrate adhesion-dependent cell spreading [BP],
regulation of establishment or maintenance of cell polarity [BP],
negative regulation of lamellipodium morphogenesis [BP],
ICAM-3 receptor activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_21_9 |
 |
 |
2 |
0.4 |
8.41E-05 |
ARRB2 |
alpha-1A adrenergic receptor binding [MF],
follicle-stimulating hormone receptor binding [MF],
type 2A serotonin receptor binding [MF] |
| CG_ffipsc1911_promoter_p_PM_12_275_4 |
 |
 |
2 |
0.4 |
1.23E-04 |
EPHX1 |
cis-stilbene-oxide hydrolase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_16_8_17 |
 |
 |
4 |
0.8 |
4.16E-05 |
TALDO1,
UGP2 |
sedoheptulose-7-phosphate:D-glyceraldehyde-3-phosphate glyceronetransferase activity [MF],
UTP:glucose-1-phosphate uridylyltransferase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_18_24_14 |
 |
 |
3 |
0.6 |
2.27E-05 |
MGST1 |
cellular response to lipid hydroperoxide [BP] |
| CG_ffipsc1911_promoter_p_PM_18_23_27 |
 |
 |
3 |
0.6 |
3.25E-05 |
AMDHD2 |
N-acetylglucosamine-6-phosphate deacetylase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_59_6 |
 |
 |
2 |
0.4 |
1.56E-04 |
SMCHD1,
MYOCD,
ITCH,
LILRB1,
CUL4A |
negative regulation of CD8-positive, alpha-beta T cell activation [BP],
negative regulation of alpha-beta T cell activation [BP],
negative regulation of type I interferon production [BP],
positive regulation of cardiac vascular smooth muscle cell differentiation [BP],
negative regulation of interferon-beta secretion [BP],
negative regulation of interleukin-10 secretion [BP],
negative regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell [BP],
negative regulation of transforming growth factor-beta secretion [BP],
negative regulation of mononuclear cell proliferation [BP],
negative regulation of osteoclast development [BP],
HLA-A specific inhibitory MHC class I receptor activity [MF],
negative regulation of interleukin-12 secretion [BP],
negative regulation of T cell proliferation [BP],
positive regulation of gamma-delta T cell activation involved in immune response [BP],
negative regulation of cell proliferation [BP],
inactivation of X chromosome by DNA methylation [BP] |
| CG_ffipsc1911_promoter_p_PM_12_225_5 |
 |
 |
1 |
0.2 |
1.99E-04 |
COL14A1 |
collagen type XIV [CC] |
| CG_ffipsc1911_promoter_p_PM_12_8_7 |
 |
 |
2 |
0.4 |
3.93E-04 |
PLK5,
F2R |
defense response to tumor cell [BP],
G-protein beta-subunit binding [MF],
negative regulation of renin secretion into blood stream [BP],
connective tissue replacement involved in inflammatory response wound healing [BP],
establishment of synaptic specificity at neuromuscular junction [BP] |
| CG_ffipsc1911_promoter_p_PM_12_273_4 |
 |
 |
4 |
0.8 |
2.05E-04 |
WRNIP1,
PNPO,
DIO3,
PSMC4,
ASL,
KYNU |
arginine biosynthetic process via ornithine [BP],
response to vitamin B6 [BP],
anthranilate metabolic process [BP],
argininosuccinate lyase activity [MF],
thyroxine 5-deiodinase activity [MF],
pyridoxamine-phosphate oxidase activity [MF],
kynureninase activity [MF],
ATP catabolic process [BP] |
| CG_ffipsc1911_promoter_p_PM_12_291_8 |
 |
 |
2 |
0.4 |
9.51E-05 |
PPCS |
phosphopantothenate--cysteine ligase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_234_7 |
 |
 |
1 |
0.2 |
4.85E-05 |
PRPSAP2,
PDK2 |
mitochondrial pyruvate dehydrogenase complex [CC],
ribose phosphate diphosphokinase complex [CC] |
| CG_ffipsc1911_promoter_p_PM_12_3_7 |
 |
 |
5 |
0.8 |
4.92E-04 |
CCDC103 |
outer dynein arm assembly [BP],
inner dynein arm assembly [BP] |
| CG_ffipsc1911_promoter_p_PM_16_22_25 |
 |
 |
6 |
0.8 |
4.74E-05 |
MAP3K13,
AKAP13,
MAP2K1 |
activation of MAPKK activity [BP],
regulation of glucocorticoid mediated signaling pathway [BP],
receptor signaling protein tyrosine phosphatase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_160_7 |
 |
 |
2 |
0.4 |
1.04E-04 |
PDZD2,
HPN,
FGFR3,
SLC5A1 |
cell-cell junction [CC],
cochlea development [BP],
basement membrane disassembly [BP] |
| CG_ffipsc1911_promoter_p_PM_12_36_4 |
 |
 |
1 |
0.2 |
9.06E-05 |
FAAH,
REST,
CAMSAP3 |
negative regulation of dense core granule biogenesis [BP],
negative regulation of amniotic stem cell differentiation [BP],
microtubule minus-end binding [MF],
fatty acid amide hydrolase activity [MF],
negative regulation of mesenchymal stem cell differentiation [BP] |
| CG_ffipsc1911_promoter_p_PM_12_174_5 |
 |
 |
2 |
0.4 |
1.45E-05 |
PLOD1 |
hydroxylysine biosynthetic process [BP] |
| CG_ffipsc1911_promoter_p_PM_14_4_10 |
 |
 |
12 |
1.0 |
2.15E-05 |
CLPSL1 |
enzyme activator activity [MF] |
| CG_ffipsc1911_promoter_p_PM_18_5_41 |
 |
 |
4 |
0.8 |
2.91E-05 |
PIPOX,
PRMT7 |
L-lysine catabolic process to acetyl-CoA via L-pipecolate [BP],
[myelin basic protein]-arginine N-methyltransferase activity [MF],
L-pipecolate oxidase activity [MF],
sarcosine oxidase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_16_37_11 |
 |
 |
2 |
0.4 |
2.45E-05 |
SPN |
negative regulation of type IV hypersensitivity [BP] |
| CG_ffipsc1911_promoter_p_PM_12_230_9 |
 |
 |
4 |
0.8 |
9.17E-05 |
SLC25A3 |
phosphate ion carrier activity [MF] |
| CG_ffipsc1911_promoter_p_PM_16_4_17 |
 |
 |
3 |
0.6 |
9.99E-05 |
ZNF587,
AACS,
ZNF774,
RNF26,
AGFG2,
SUV39H2 |
acetoacetate-CoA ligase activity [MF],
cellular response to testosterone stimulus [BP],
zinc ion binding [MF] |
| CG_ffipsc1911_promoter_p_PM_12_296_13 |
 |
 |
3 |
0.6 |
8.62E-05 |
PRKAR2B,
SPHK1 |
D-erythro-sphingosine kinase activity [MF],
sphingoid catabolic process [BP],
response to antipsychotic drug [BP],
sphinganine kinase activity [MF],
response to clozapine [BP] |
| CG_ffipsc1911_promoter_p_PM_16_34_15 |
 |
 |
4 |
0.8 |
3.93E-05 |
ULK1,
LARP1 |
positive regulation of macroautophagy [BP],
positive regulation of autophagy [BP] |
| CG_ffipsc1911_promoter_p_PM_12_176_6 |
 |
 |
2 |
0.4 |
1.14E-04 |
ALDOA |
fructose binding [MF],
fructose 1,6-bisphosphate metabolic process [BP],
fructose-bisphosphate aldolase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_14_2_20 |
 |
 |
10 |
1.0 |
4.79E-05 |
CDC42EP1,
PDZD3,
F2RL1,
NPM1,
DRD4,
ERAL1,
NPR1 |
ribosomal small subunit binding [MF],
positive regulation of pseudopodium assembly [BP],
receptor guanylyl cyclase signaling pathway [BP],
regulation of dopamine metabolic process [BP],
dopamine metabolic process [BP] |
| CG_ffipsc1911_promoter_p_PM_12_89_10 |
 |
 |
2 |
0.4 |
4.06E-04 |
DAND5,
MDH2,
HCK |
sequestering of nodal from receptor via nodal binding [BP],
respiratory burst after phagocytosis [BP],
malate dehydrogenase (NADP+) activity [MF],
negative regulation of nodal signaling pathway [BP],
leukocyte migration involved in immune response [BP] |
| CG_ffipsc1911_promoter_p_PM_12_243_8 |
 |
 |
3 |
0.6 |
6.57E-05 |
TYR |
monophenol monooxygenase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_95_7 |
 |
 |
2 |
0.4 |
1.78E-04 |
MYC |
negative regulation of G2 phase of mitotic cell cycle [BP],
positive regulation of metanephric cap mesenchymal cell proliferation [BP] |
| CG_ffipsc1911_promoter_p_PM_18_8_46 |
 |
 |
4 |
0.8 |
4.36E-05 |
MTMR14,
SACM1L,
MERTK,
CDC42,
NCOA3 |
vagina development [BP],
regulation of filopodium assembly [BP],
filopodium assembly [BP],
phosphatidylinositol-3-phosphatase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_132_5 |
 |
 |
2 |
0.4 |
5.91E-05 |
ADCYAP1,
EIF2B2 |
ovarian follicle development [BP],
positive regulation of somatostatin secretion [BP],
pituitary adenylate cyclase-activating polypeptide receptor binding [MF],
pituitary adenylate cyclase activating polypeptide activity [MF],
negative regulation of acute inflammatory response to non-antigenic stimulus [BP] |
| CG_ffipsc1911_promoter_p_PM_14_9_6 |
 |
 |
4 |
0.8 |
9.60E-05 |
PAPSS2,
DPPA3 |
negative regulation of DNA demethylation [BP],
protection of DNA demethylation of female pronucleus [BP],
3'-phosphoadenosine 5'-phosphosulfate biosynthetic process [BP] |
| CG_ffipsc1911_promoter_p_PM_12_226_10 |
 |
 |
2 |
0.4 |
4.19E-05 |
MAML1 |
MAML1-RBP-Jkappa- ICN1 complex [CC],
atrioventricular node cell development [BP],
atrioventricular node development [BP] |
| CG_ffipsc1911_promoter_p_PM_16_20_19 |
 |
 |
5 |
0.8 |
3.43E-05 |
SLC9A8,
AQP9,
SLC4A2,
ATP6V1B1,
ATP2B4,
SLC38A3 |
transmembrane transport [BP],
antiporter activity [MF] |
| CG_ffipsc1911_promoter_p_PM_14_62_10 |
 |
 |
2 |
0.4 |
2.08E-05 |
CLYBL,
SPR,
SLC51A,
SLC51B,
JAK2,
PGD |
nitric oxide metabolic process [BP],
nitric oxide biosynthetic process [BP],
bile acid and bile salt transport [BP],
mineralocorticoid receptor signaling pathway [BP],
citrate (pro-3S)-lyase activity [MF],
NADP binding [MF],
histone kinase activity (H3-Y41 specific) [MF],
histone H3-Y41 phosphorylation [BP],
sepiapterin reductase activity [MF],
activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway [BP] |
| CG_ffipsc1911_promoter_p_PM_18_9_19 |
 |
 |
4 |
0.8 |
6.90E-05 |
PEX14,
SNCG |
beta-tubulin binding [MF] |
| CG_ffipsc1911_promoter_p_PM_14_11_10 |
 |
 |
1 |
0.2 |
1.99E-05 |
ENGASE,
SLC13A2 |
low affinity sodium:dicarboxylate symporter activity [MF],
mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_292_11 |
 |
 |
3 |
0.6 |
1.99E-04 |
RAC1 |
epithelial cell morphogenesis [BP] |
| CG_ffipsc1911_promoter_p_PM_12_44_13 |
 |
 |
2 |
0.4 |
8.55E-05 |
RNF5,
OS9 |
Hrd1p ubiquitin ligase complex [CC],
ER-associated protein catabolic process [BP],
ER-associated misfolded protein catabolic process [BP] |
| CG_ffipsc1911_promoter_p_PM_14_71_7 |
 |
 |
4 |
0.8 |
4.62E-05 |
ERCC4 |
nucleotide-excision repair factor 1 complex [CC] |
| CG_ffipsc1911_promoter_p_PM_12_169_11 |
 |
 |
4 |
0.8 |
1.47E-04 |
HIPK1,
POR,
TET3,
VARS2 |
iron-cytochrome-c reductase activity [MF],
cellular organofluorine metabolic process [BP],
valyl-tRNA aminoacylation [BP],
DNA demethylation of male pronucleus [BP],
nitric oxide catabolic process [BP],
regulation of growth plate cartilage chondrocyte proliferation [BP],
nitrate catabolic process [BP],
demethylation [BP],
valine-tRNA ligase activity [MF],
smoothened signaling pathway [BP] |
| CG_ffipsc1911_promoter_p_PM_16_19_25 |
 |
 |
5 |
1.0 |
9.46E-05 |
GATC,
SAT1 |
regulation of translational fidelity [BP],
spermidine binding [MF],
diamine N-acetyltransferase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_222_6 |
 |
 |
1 |
0.2 |
4.91E-05 |
MOV10 |
mRNA cleavage involved in gene silencing by miRNA [BP] |
| CG_ffipsc1911_promoter_p_PM_14_58_11 |
 |
 |
3 |
0.6 |
2.01E-05 |
PDP2 |
magnesium-dependent protein serine/threonine phosphatase activity [MF],
[pyruvate dehydrogenase (lipoamide)] phosphatase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_194_11 |
 |
 |
2 |
0.4 |
3.85E-05 |
FDFT1,
GM2A |
farnesyl-diphosphate farnesyltransferase activity [MF],
sphingolipid activator protein activity [MF],
squalene synthase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_154_10 |
 |
 |
3 |
0.6 |
4.80E-05 |
FOXO3 |
initiation of primordial ovarian follicle growth [BP] |
| CG_ffipsc1911_promoter_p_PM_12_26_9 |
 |
 |
2 |
0.4 |
1.41E-04 |
RASL10B,
GAPDHS,
UHRF1 |
positive regulation of DNA topoisomerase (ATP-hydrolyzing) activity [BP],
regulation of systemic arterial blood pressure by atrial natriuretic peptide [BP],
glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity [MF],
nucleosomal histone binding [MF],
hemi-methylated DNA-binding [MF] |
| CG_ffipsc1911_promoter_p_PM_12_87_5 |
 |
 |
2 |
0.4 |
3.58E-05 |
CR2 |
complement receptor activity [MF] |
| CG_ffipsc1911_promoter_p_PM_14_23_10 |
 |
 |
4 |
0.6 |
4.03E-05 |
KDM4A,
MAN2A2,
KAT8 |
methylated histone residue binding [MF],
hydrolase activity, hydrolyzing N-glycosyl compounds [MF] |
| CG_ffipsc1911_promoter_p_PM_12_179_6 |
 |
 |
3 |
0.6 |
7.10E-05 |
CSF1,
DRD4 |
mammary gland fat development [BP],
olfactory learning [BP] |
| CG_ffipsc1911_promoter_p_PM_12_248_23 |
 |
 |
4 |
0.6 |
1.21E-04 |
DSP,
CBR1 |
15-hydroxyprostaglandin dehydrogenase (NADP+) activity [MF],
protein localization to adherens junction [BP],
carbonyl reductase (NADPH) activity [MF],
ventricular compact myocardium morphogenesis [BP],
prostaglandin-E2 9-reductase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_81_5 |
 |
 |
1 |
0.2 |
2.85E-04 |
TUBB6 |
'de novo' posttranslational protein folding [BP] |
| CG_ffipsc1911_promoter_p_PM_14_21_10 |
 |
 |
3 |
0.6 |
1.29E-05 |
NGFR,
SPHK1 |
sphingoid catabolic process [BP],
positive regulation of fibroblast proliferation [BP] |
| CG_ffipsc1911_promoter_p_PM_14_6_9 |
 |
 |
3 |
0.6 |
6.49E-05 |
B4GALT7,
MLL,
TIPARP |
xylosylprotein 4-beta-galactosyltransferase activity [MF],
positive regulation of cellular response to drug [BP],
nucleic acid binding [MF] |
| CG_ffipsc1911_promoter_p_PM_12_67_4 |
 |
 |
2 |
0.4 |
1.28E-04 |
CNP,
RAG1 |
endonuclease activity [MF],
pre-B cell allelic exclusion [BP],
2',3'-cyclic-nucleotide 3'-phosphodiesterase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_285_11 |
 |
 |
4 |
0.6 |
1.88E-04 |
LMTK2,
SERPINA5 |
protein C inhibitor-PLAT complex [CC],
protein C inhibitor-thrombin complex [CC],
protein C inhibitor-coagulation factor V complex [CC],
protein C inhibitor-TMPRSS7 complex [CC],
protein C inhibitor-coagulation factor Xa complex [CC],
myosin VI binding [MF],
protein C inhibitor-KLK3 complex [CC],
protein C inhibitor-TMPRSS11E complex [CC],
protein C inhibitor-coagulation factor XI complex [CC],
protein C inhibitor-PLAU complex [CC],
protein C inhibitor-plasma kallikrein complex [CC] |
| CG_ffipsc1911_promoter_p_PM_12_181_7 |
 |
 |
2 |
0.4 |
8.30E-05 |
CDK13 |
cyclin K-CDK13 complex [CC],
phosphorylation of RNA polymerase II C-terminal domain [BP] |
| CG_ffipsc1911_promoter_p_PM_12_294_5 |
 |
 |
2 |
0.4 |
1.30E-04 |
PEX14,
RANBP1 |
peroxisome transport along microtubule [BP],
positive regulation of mitotic centrosome separation [BP],
protein import into peroxisome matrix, substrate release [BP] |
| CG_ffipsc1911_promoter_p_PM_12_85_8 |
 |
 |
3 |
0.6 |
1.48E-04 |
UVSSA,
ELANE |
response to UV [BP] |
| CG_ffipsc1911_promoter_p_PM_12_200_17 |
 |
 |
2 |
0.4 |
2.49E-05 |
IKZF1,
ABCD1 |
peroxisomal long-chain fatty acid import [BP],
positive regulation of neutrophil differentiation [BP],
peroxisomal fatty-acyl-CoA transporter activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_54_9 |
 |
 |
2 |
0.4 |
1.21E-04 |
FUK,
PDPK1 |
3-phosphoinositide-dependent protein kinase activity [MF],
fucokinase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_2_9 |
 |
 |
2 |
0.4 |
4.14E-05 |
HTT |
neural plate formation [BP],
diazepam binding [MF] |
| CG_ffipsc1911_promoter_p_PM_12_102_5 |
 |
 |
2 |
0.4 |
7.99E-05 |
ACSF3 |
malonate catabolic process [BP],
malonyl-CoA synthetase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_121_9 |
 |
 |
3 |
0.6 |
1.52E-04 |
TUBA8,
ARL2,
SEPT9,
ACADM,
PFAS,
NCAPH2 |
medium-chain fatty acid catabolic process [BP],
GTPase activity [MF],
chromosome condensation [BP],
phosphoribosylformylglycinamidine synthase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_14_65_4 |
 |
 |
1 |
0.2 |
5.59E-05 |
ZMPSTE24,
RBCK1 |
protein linear polyubiquitination [BP],
prenylated protein catabolic process [BP],
LUBAC complex [CC] |
| CG_ffipsc1911_promoter_p_PM_14_7_5 |
 |
 |
1 |
0.2 |
2.35E-05 |
NTRK2 |
brain-derived neurotrophic factor binding [MF],
brain-derived neurotrophic factor receptor signaling pathway [BP],
brain-derived neurotrophic factor-activated receptor activity [MF] |
| CG_ffipsc1911_promoter_p_PM_14_57_11 |
 |
 |
4 |
0.6 |
6.24E-05 |
NF2,
RAB8A |
negative regulation of tyrosine phosphorylation of Stat5 protein [BP],
Golgi vesicle fusion to target membrane [BP] |
| CG_ffipsc1911_promoter_p_PM_12_216_10 |
 |
 |
1 |
0.2 |
3.03E-04 |
VAPB,
GABARAPL2,
PLN |
beta-tubulin binding [MF],
negative regulation of calcium ion binding [BP],
ATPase inhibitor activity [MF],
regulation of relaxation of cardiac muscle [BP],
negative regulation of calcium-transporting ATPase activity [BP],
adrenergic receptor signaling pathway involved in heart process [BP],
ATPase binding [MF],
regulation of the force of heart contraction by cardiac conduction [BP] |
| CG_ffipsc1911_promoter_p_PM_12_106_8 |
 |
 |
2 |
0.4 |
2.28E-04 |
HSD3B7 |
cholest-5-ene-3-beta,7-alpha-diol 3-beta-dehydrogenase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_14_48_7 |
 |
 |
1 |
0.2 |
1.39E-05 |
PSEN1,
IDO2 |
choline transport [BP],
regulation of resting membrane potential [BP],
gamma-secretase complex [CC],
Cajal-Retzius cell differentiation [BP],
synaptic vesicle targeting [BP],
smooth endoplasmic reticulum calcium ion homeostasis [BP],
negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process [BP],
tryptophan 2,3-dioxygenase activity [MF],
indoleamine 2,3-dioxygenase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_295_11 |
 |
 |
3 |
0.6 |
1.31E-04 |
PTBP1 |
negative regulation of muscle cell differentiation [BP] |
| CG_ffipsc1911_promoter_p_PM_12_185_4 |
 |
 |
2 |
0.4 |
1.78E-04 |
PVRL2,
ALLC,
LCMT1 |
allantoicase activity [MF],
virion attachment, binding of host cell surface coreceptor [BP],
allantoin catabolic process [BP],
protein C-terminal carboxyl O-methyltransferase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_122_10 |
 |
 |
2 |
0.4 |
5.65E-05 |
CTF1,
NADSYN1 |
leukemia inhibitory factor receptor binding [MF],
NAD+ synthase (glutamine-hydrolyzing) activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_34_14 |
 |
 |
2 |
0.4 |
2.47E-05 |
NQO2,
MARC2,
GM2A,
BLOC1S4 |
sphingolipid activator protein activity [MF],
dihydronicotinamide riboside quinone reductase activity [MF],
NADPH dehydrogenase (quinone) activity [MF],
neuromuscular process controlling balance [BP],
nitrate reductase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_284_11 |
 |
 |
4 |
0.8 |
3.43E-04 |
SLC34A2,
PAFAH1B1,
GTF2F2,
C5AR2 |
establishment of centrosome localization [BP],
transcription factor TFIIF complex [CC],
astral microtubule [CC],
C5a anaphylatoxin receptor activity [MF],
response to fructose stimulus [BP],
dynein intermediate chain binding [MF],
osteoclast development [BP],
nuclear envelope disassembly [BP] |
| CG_ffipsc1911_promoter_p_PM_12_172_17 |
 |
 |
3 |
0.6 |
3.13E-05 |
PPP1CB,
LDLRAP1,
NR1H3,
PSMC5 |
myosin phosphatase activity [MF],
negative regulation of secretion of lysosomal enzymes [BP],
myosin-light-chain-phosphatase activity [MF],
cholesterol homeostasis [BP],
thyrotropin-releasing hormone receptor binding [MF],
sterol homeostasis [BP] |
| CG_ffipsc1911_promoter_p_PM_12_236_11 |
 |
 |
1 |
0.2 |
8.15E-05 |
NTSR1,
KIF26A |
G-protein coupled neurotensin receptor activity [MF],
regulation of cell growth by extracellular stimulus [BP] |
| CG_ffipsc1911_promoter_p_PM_14_55_7 |
 |
 |
4 |
0.6 |
2.96E-05 |
IPO5 |
nuclear pore [CC] |
| CG_ffipsc1911_promoter_p_PM_14_41_7 |
 |
 |
3 |
0.6 |
2.59E-05 |
ATF1,
CDK14,
MLL,
TLR3 |
toll-like receptor 4 signaling pathway [BP],
toll-like receptor 3 signaling pathway [BP],
cytoplasmic cyclin-dependent protein kinase holoenzyme complex [CC],
positive regulation of type III interferon production [BP],
TRIF-dependent toll-like receptor signaling pathway [BP],
Toll signaling pathway [BP],
MyD88-independent toll-like receptor signaling pathway [BP],
positive regulation of cellular response to drug [BP] |
| CG_ffipsc1911_promoter_p_PM_12_48_8 |
 |
 |
3 |
0.6 |
7.77E-05 |
PRMT1,
ACR |
acrosome matrix dispersal [BP],
snoRNP binding [MF],
amidase activity [MF],
[cytochrome c]-arginine N-methyltransferase activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_42_5 |
 |
 |
1 |
0.2 |
1.70E-05 |
GATA6 |
negative regulation of transforming growth factor beta2 production [BP] |
| CG_ffipsc1911_promoter_p_PM_12_11_8 |
 |
 |
1 |
0.2 |
1.66E-05 |
SMPD1,
PHF17 |
sphingomyelin catabolic process [BP],
histone H4-K12 acetylation [BP] |
| CG_ffipsc1911_promoter_p_PM_14_37_25 |
 |
 |
4 |
0.6 |
1.20E-04 |
PSMD8,
SART1 |
positive regulation of cytotoxic T cell differentiation [BP],
RNA metabolic process [BP] |
| CG_ffipsc1911_promoter_p_PM_12_46_12 |
 |
 |
3 |
0.6 |
5.62E-05 |
NEIL1,
EIF5AL1 |
negative regulation of nuclease activity [BP],
positive regulation of translational elongation [BP],
translational frameshifting [BP],
positive regulation of translational termination [BP],
peptidyl-lysine modification to hypusine [BP] |
| CG_ffipsc1911_promoter_p_PM_16_10_16 |
 |
 |
4 |
0.8 |
1.61E-05 |
SPP1,
MSH3 |
dinucleotide insertion or deletion binding [MF],
dinucleotide repeat insertion binding [MF],
loop DNA binding [MF],
MutSbeta complex [CC],
double-strand/single-strand DNA junction binding [MF],
single guanine insertion binding [MF],
negative regulation of collateral sprouting of intact axon in response to injury [BP] |
| CG_ffipsc1911_promoter_p_PM_12_173_13 |
 |
 |
2 |
0.4 |
7.52E-05 |
ITGAV,
ATP1B2 |
leukocyte migration [BP] |
| CG_ffipsc1911_promoter_p_PM_12_258_10 |
 |
 |
2 |
0.4 |
1.04E-04 |
SLC22A5 |
sodium-dependent organic cation transport [BP],
positive regulation of intestinal epithelial structure maintenance [BP],
quorum sensing involved in interaction with host [BP] |
| CG_ffipsc1911_promoter_p_PM_12_241_4 |
 |
 |
2 |
0.4 |
3.63E-05 |
ICAM1,
POR |
T cell antigen processing and presentation [BP],
iron-cytochrome-c reductase activity [MF],
response to sulfur dioxide [BP],
response to gonadotropin stimulus [BP],
nitric oxide catabolic process [BP],
nitrate catabolic process [BP] |
| CG_ffipsc1911_promoter_p_PM_12_141_4 |
 |
 |
2 |
0.4 |
1.71E-04 |
SLC50A1,
EPHX1 |
glucoside transport [BP],
cis-stilbene-oxide hydrolase activity [MF],
glucoside transmembrane transporter activity [MF] |
| CG_ffipsc1911_promoter_p_PM_12_20_5 |
 |
 |
2 |
0.4 |
8.11E-05 |
CNP,
TGS1 |
2',3'-cyclic-nucleotide 3'-phosphodiesterase activity [MF],
RNA trimethylguanosine synthase activity [MF],
7-methylguanosine cap hypermethylation [BP] |
| CG_ffipsc1911_promoter_p_PM_12_69_11 |
 |
 |
2 |
0.4 |
9.34E-05 |
HIF1AN,
PML |
peptidyl-histidine hydroxylation [BP],
peptidyl-asparagine 3-dioxygenase activity [MF],
extrinsic to endoplasmic reticulum membrane [CC],
peptidyl-histidine dioxygenase activity [MF],
negative regulation of translation in response to oxidative stress [BP],
peptidyl-asparagine hydroxylation [BP] |
| CG_ffipsc1911_promoter_p_PM_14_29_20 |
 |
 |
3 |
0.6 |
1.68E-05 |
VPS45,
AGRN,
SCFD1 |
vesicle docking involved in exocytosis [BP],
positive regulation of synaptic growth at neuromuscular junction [BP] |
| CG_ffipsc1911_promoter_p_PM_12_40_5 |
 |
 |
3 |
0.6 |
2.62E-05 |
FLVCR1,
MDK |
defecation [BP],
heme export [BP] |
| CG_ffipsc1911_promoter_p_PM_12_155_9 |
 |
 |
2 |
0.4 |
2.70E-05 |
MTO1 |
mitochondrial tRNA wobble uridine modification [BP] |
| CG_ffipsc1911_promoter_p_PM_12_288_5 |
 |
 |
2 |
0.4 |
6.09E-05 |
EEF2K |
elongation factor-2 kinase activity [MF] |